Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS?

被引:38
作者
Stirewalt, Derek L. [1 ,2 ]
Mhyre, Andrew J. [1 ]
Marcondes, Mario [1 ]
Pogosova-Agadjanyan, Era [1 ]
Abbasi, Nissa [1 ]
Radich, Jerald P. [1 ,2 ]
Deeg, H. Joachim [1 ,2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA
[2] Univ Washington, Div Oncol, Seattle, WA 98195 USA
关键词
stroma; tumour necrosis factor alpha gene; expression; myelodysplasia; apoptosis;
D O I
10.1111/j.1365-2141.2007.06923.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aberrant regulation of the tumour necrosis factor alpha gene (TNF) and stroma-derived signals are involved in the pathophysiology of myelodysplasia. Therefore, KG1a, a myeloid leukaemia cell line, was exposed to Tnf in the absence or presence of either HS-5 or HS-27a cells, two human stroma cell lines. While KG1a cells were resistant to Tnf-induced apoptosis in the absence of stroma cells, Tnf-promoted apoptosis of KG1a cells in co-culture experiments with stroma cells. To investigate the Tnf-induced signals from the stroma cells, we examined expression changes in HS-5 and HS-27a cells after Tnf exposure. DNA microarray studies found both discordant and concordant Tnf-induced expression responses in the two stroma cell lines. Tnf promoted an increased mRNA expression of pro-inflammatory cytokines [e.g. interleukin (IL)6, IL8 and IL32]. At the same time, Tnf decreased the mRNA expression of anti-apoptotic genes (e.g. BCL2L1) and increased the mRNA expression of pro-apoptotic genes (e.g. BID). Overall, the results suggested that Tnf induced a complex set of pro-inflammatory and pro-apoptotic signals in stroma cells that promote apoptosis in malignant myeloid clones. Additional studies will be required to determine which of these signals are critical for the induction of apoptosis in the malignant clones. Those insights, in turn, may point the way to novel therapeutic approaches.
引用
收藏
页码:444 / 453
页数:10
相关论文
共 70 条
[1]   Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].
Aguayo, A ;
Kantarjian, H ;
Manshouri, T ;
Gidel, C ;
Estey, E ;
Thomas, D ;
Koller, C ;
Estrov, Z ;
O'Brien, S ;
Keating, M ;
Freireich, E ;
Albitar, M .
BLOOD, 2000, 96 (06) :2240-2245
[2]   Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro [J].
Aizawa, S ;
Nakano, M ;
Iwase, O ;
Yaguchi, M ;
Hiramoto, M ;
Hoshi, H ;
Nabeshima, R ;
Shima, D ;
Handa, H ;
Toyama, K .
LEUKEMIA RESEARCH, 1999, 23 (03) :239-246
[3]  
Alexandrakis M, 1998, HAEMATOLOGIA, V29, P13
[4]  
ALLEN TD, 1984, EXP HEMATOL, V12, P517
[5]  
AYANLARBATUMAN O, 1987, BLOOD, V70, P494
[6]   Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes [J].
Bellamy, WT ;
Richter, L ;
Sirjani, D ;
Roxas, C ;
Glinsmann-Gibson, B ;
Frutiger, Y ;
Grogan, TM ;
List, AF .
BLOOD, 2001, 97 (05) :1427-1434
[7]   NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors [J].
Benito, AI ;
Bryant, E ;
Loken, MR ;
Sale, GE ;
Nash, RA ;
Gass, MJ ;
Deeg, HJ .
LEUKEMIA RESEARCH, 2003, 27 (05) :425-436
[8]  
BERGER M, 1988, BLOOD, V71, P151
[9]   A comparison of normalization methods for high density oligonucleotide array data based on variance and bias [J].
Bolstad, BM ;
Irizarry, RA ;
Åstrand, M ;
Speed, TP .
BIOINFORMATICS, 2003, 19 (02) :185-193
[10]   Targeted therapies in myelodysplastic syndromes: ASH 2003 review [J].
Candoni, A ;
Silvestri, F ;
Buonamici, S ;
Li, DL ;
Reddy, P ;
Galili, N ;
Nucifora, G ;
Raza, A .
SEMINARS IN HEMATOLOGY, 2004, 41 (02) :13-20